Tag Directory / PHARMACEUTICALS     showing 41–60 of 108



Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment


Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days


Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO / Endpoints

Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...

#healthcare #pharmaceuticals #biotech #drugdevelopment


Saturday, February 14, 2026, 3:20 am / permalink 19177 / 3 stories in 25 days


Ama launches independent vaccine review after CDC criticism / Medical Express

medicalxpress - Two major medical groups will begin reviewing vaccine safety and effectiveness after major changes at the U.S. Centers for Disease Control and Prevention (CDC) have raised alarms among experts.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #cdc #vaccinesafety


Saturday, February 14, 2026, 12:22 am / permalink 19173 / 4 stories in 25 days


BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 25 days


AbbVie sues over selection of Botox for IRA negotiations / Endpoints

Nicole DeFeudis / endpoints - AbbVie is suing CMS for picking Botox for the third round of Medicare negotiations, making it the first drugmaker to challenge the upcoming cycle in court. In a lawsuit filed Wednesday in Washington, DC, AbbVie ...

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy


Saturday, February 14, 2026, 12:22 am / permalink 19169 / 2 stories in 25 days


FDA refuses to review Moderna flu vaccine / Beckers

Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Wednesday, February 11, 2026, 10:25 am / permalink 19026 / 15 stories in 28 days


AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo / Endpoints

Anna Brown / endpoints - The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Monday, February 9, 2026, 12:21 am / permalink 18917 / 5 stories in 4 wks


World Cancer Day: A Global Call to Awareness and Action 2026, Part 2 / OncoDaily

oncodaily - World Cancer Day is observed annually on February 4 and was established in 2000 at the World Summit Against Cancer for the New Millennium in Paris. The initiative was led […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment


Early Detection & Access Initiatives


Other Cancer News


Research and Treatment Advances


World Cancer Day Global Events


All Other Stories


Saturday, February 7, 2026, 3:21 pm / permalink 18896 / 162 stories in 4 wks


HHS to drop 340B rebate pilot after court rulings / Beckers

Ella Jeffries / beckershospitalreview - HHS will drop its 340B rebate model pilot program following two federal court rulings that blocked its implementation. The program, announced in August 2025, was challenged by the American Hospital Association, the Maine Hospital Association and four safe…

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy


Saturday, February 7, 2026, 6:21 am / permalink 18879 / 3 stories in 4 wks


#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial / Endpoints

Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, February 7, 2026, 3:21 am / permalink 18873 / 2 stories in 4 wks


Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery / OncoDaily

oncodaily - Eikon Therapeutics has raised $381 million through its IPO, pricing at the top of its range in a strong sign of renewed investor appetite for biotech offerings. The South San […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, February 7, 2026, 1:21 am / permalink 18871 / 2 stories in 4 wks


HHS scraps 340B rebate pilot in win for hospitals / Healthcare Dive

Emily Olsen / healthcaredive - The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates on some drugs instead of upfront discounts.

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy


Saturday, February 7, 2026, 12:23 am / permalink 18867 / 5 stories in 4 wks


Statin pills much safer than advertised, major review finds / BBC

bbc - The results, in The Lancet journal, come from trials involving more than 120,000 people comparing statins with a dummy drug or placebo.

#healthcare #pharmaceuticals #publichealth


Thursday, February 5, 2026, 8:24 pm / permalink 18820 / 3 stories in 4 wks


Novo Nordisk vows legal action to protect Wegovy pill / Medical Express

medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #drugdevelopment #digitalhealth


Thursday, February 5, 2026, 3:23 pm / permalink 18807 / 22 stories in 4 wks


FTC deal over insulin prices forces Express Scripts to overhaul policies / Beckers

Elizabeth Casolo / beckershospitalreview - The Federal Trade Commission reached a settlement with Cigna’s Express Scripts in a case over alleged inflation of insulin prices, according to a Feb. 4 agency news release. Under the settlement, Express Scripts must keep drug manufacturer compensation de…

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy


Wednesday, February 4, 2026, 3:25 pm / permalink 18768 / 6 stories in 4 wks


Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade / Calgary Sun

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, January 31, 2026, 2:22 pm / permalink 18622 / 9 stories in 5 wks


FDA lifts hold on one of two Phase 3 gene editing studies by Intellia / Endpoints

Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Saturday, January 31, 2026, 7:22 am / permalink 18610 / 4 stories in 5 wks


‘Vertical integration is destroying people’s ability to access care’: Payer CEOs face bipartisan congressional grilling / Beckers

Jakob Emerson / beckershospitalreview - The CEOs of the nation’s largest health insurers drew the ire of lawmakers on both sides of the aisle during congressional hearings Jan. 22 over industry consolidation, prior authorization practices and executive pay, with members pressing executives to e…

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #mergersandacquisitions #corporatetakeover


Thursday, January 22, 2026, 9:22 pm / permalink 18314 / 27 stories in 6 wks


#JPM26: Day 3 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s Wednesday at the JP Morgan Healthcare Conference, and as the sessions wind down, we’ll be keeping an eye on presentations from WuXi AppTec and AbbVie. Yesterday afternoon, our Executive Editor Drew Armstrong spoke with ...

#obesity #healthcare #pharmaceuticals #weightloss #biotech #drugdevelopment #digitalhealth


Saturday, January 17, 2026, 7:21 pm / permalink 18138 / 28 stories in 7 wks


F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds / NYT

Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda


Saturday, January 17, 2026, 8:21 am / permalink 18126 / 5 stories in 7 wks


Back to Top


PHARMACEUTICALS Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.